I've seen this concern raised by others as well. If the Mortality rate decreases because of SOC, it will decrease in both populations, which still gives Leronlimab the ability to show an improvement.

The lower the mortality goes, the larger the n will need to be to provide a sufficient p value. But, the SOC has not improved that much, so I am not concerned about it.

I think some people are conflating the reduced fatality nationwide with improved SOC. This is more likely the result of the average age of the infected dropping.

More young people getting sick + less older people getting sick = lower fatality rate. This element has no bearing on our trials.